

I hereby certify that this correspondence is being filed via
EFS-Web with the United States Patent and Trademark Office
on MAY 13, 2009

TOWNSEND and TOWNSEND and CREW LLP

By: Kimberly Hebert

**AMENDMENT UNDER 37 CFR 1.116
EXPEDITED PROCEDURE –
EXAMINING GROUP 1642**

PATENT

Attorney Docket No.: 02307K-141581US

Client Ref. No.: UCLA Reference No.: 97-575-B

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of:

Robert E. Reiter et al.

Application No.: 09/854,811

Filed: May 14, 2001

For: METHODS FOR INDUCING AN
IMMUNE RESPONSE TO CANCERS
EXPRESSING PSCA

Customer No.: 20350

Confirmation No. 9472

Examiner: Peter J. Reddig

Technology Center/Art Unit: 1642

RESUBMITTED AMENDMENT UNDER
37 CFR 1.116 EXPEDITED PROCEDURE
EXAMINING GROUP 1642 IN
RESPONSE TO NOTICE OF NON-
COMPLIANT AMENDMENT

Mail Stop AF
Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Sir:

Applicants wish to resubmit the non-compliant after-final Amendment, with corrections, in response to the Final Office Action mailed October 10, 2008 on the above-referenced application. Due to a clerical error in the non-compliant after-final Amendment filed April 10, 2009, the Applicants had included two page twos and had left out page 3. This error has now been corrected. Applicants have further proofed the claims to help assure that all changes are indicated. The amendments to the claims add no new matter and the Applicants respectfully request their entry. The **entire corrected Amendment** is being submitted herewith.

It is noted that the Examiner has acknowledged receipt of the Notice of Appeal and Petition to Extend Time that was filed with the non-compliant after-final Amendment on April 10, 2009.

Appl. No. 09/854,811
Amdt. dated May 13, 2009
Amendment under 37 CFR 1.116 Expedited Procedure
Examining Group 1642

PATENT

Amendments to the Claims are reflected in the listing of claims which begins on page 3 of this paper.

Remarks/Arguments begin on page 5 of this paper.

An **Appendix** consisting of a reference from Molecular Therapy (2009), is attached following page 7 of this paper.